Research
Stopping GLP-1 treatment linked to higher cardiovascular risk in diabetes
In an observational study, people with type 2 diabetes who stopped GLP-1 treatment had about twice the combined risk of heart attack, stroke or death as those who continued.
A study found that people with type 2 diabetes and no established cardiovascular disease who stopped GLP-1 treatment had about twice the combined risk of nonfatal heart attack, nonfatal stroke or death from any cause compared with people who continued treatment. The study was published in The Lancet Regional Health, Europe.
The combined outcome occurred at roughly four events per 100 people per year among those who stopped treatment, compared with two per 100 among those who continued. The study was observational, so it cannot establish whether stopping directly raised risk. Researchers did not know why people stopped, and say more research is needed to clarify the link.
